Clinical significance of high levels of soluble tumour necrosis factor-α receptor-2 produced by alternative splicing in rheumatoid arthritis: A longitudinal prospective cohort study

Rheumatology

Volumn 50, Issue 4, 2011, Pages 721-728

  Cañete, Juan D ^a   Albaladejo, Carolina ^a   Hernández, Maria Victoria ^a   Laínez, Begoña ^b   Pinto, José A ^c   Ramírez, Julio ^a   López Armada, Maria José ^c   Rodríguez Cros, José R ^a   Engel, Pablo ^b   Blanco, Francisco J ^c   Sanmartí, Raimon ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Anti tumour necrosis factor therapy; European League Against Rheumatism response; Radiographic progression; Rheumatoid arthritis; Synthetic disease modifying anti rheumatic drug; Tumour necrosis factor receptors

Indexed keywords

AUROTHIOMALATE; INFLIXIMAB; INTERSTITIAL COLLAGENASE; METHOTREXATE; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; ALTERNATIVE RNA SPLICING; ARTICLE; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADULT; ALTERNATIVE SPLICING; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MATRIX METALLOPROTEINASE 1; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952796996     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq381     Document Type: Article

References (24)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
2. Xanthoulea S, Pasparakis M, Kousteni S et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 2004;200:367-76.
3. Levine SJ. Mechanisms of soluble cytokine receptor generation. J Immunol 2004;173:5343-8.
4. Modrek B, Resch A, Grasso C, Lee C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res 2001;29:2850-9.
5. Lainez B, Fernandez-Real JM, Romero X et al. Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2. Int Immunol 2004;16:169-77.
6. Cope AP, Aderka D, Doherty M et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35:1160-9.
7. Mattey DL, Glossop JR, Nixon NB, Dawes PT. Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3940-8.
8. Karlson EW, Chibnik LB, Tworoger SS et al. Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis Rheum 2009;60:641-52.
9. Heaney ML, Golde DW. Soluble receptors in human disease. J Leukoc Biol 1998;64:135-46.
10. Mohler KM, Torrance DS, Smith CA et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
11. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
12. Sanmarti R, Gomez A, Ercilla G et al. Radiological progression in early rheumatoid arthritis after DMARDS: a one-year follow-up study in a clinical setting. Rheumatology 2003;42:1044-9.
13. Kirwan JR. Using the Larsen index to assess radiographic progression in rheumatoid arthritis. J Rheumatol 2000;27: 264-8.
14. Bruynesteyn K, van der Heijde D, Boers M et al. Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: preliminary results of a validation study with clinical experts. J Rheumatol 2001;28:904-10.
15. Cañete JD, Suárez B, Hernández MV et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1547-52.
16. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175:323-9.
17. Young-Min S, Cawston T, Marshall N et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007;56:3236-47.
18. Rooney T, Roux-Lombard P, Veale DJ, FitzGerald O, Dayer JM, Bresnihan B. Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomized clinical trial of cytokine blockade. Ann Rheum Dis 2010;69:706-14.
19. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 2003;42:677-80.
20. Barrera P, Boerbooms AM, Janssen EM et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993;36:1070-9.
21. Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:660-9.
22. Klimiuk PA, Sierakowski S, Latosiewicz R et al. Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann Rheum Dis 2003; 62:472-5.
23. Tolusso B, Sacco S, Gremese E, La Torre G, Tomietto P, Ferraccioli GF. Relationship between the tumor necrosis factor receptor II (TNF-RII) gene polymorphism and sTNF-RII plasma levels in healthy controls and in rheumatoid arthritis. Hum Immunol 2004;65: 1420-6.
24. Glossop JR, Dawes PT, Nixon NB, Mattey DL. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Arthritis Res Ther 2005;7:R1227-34.